Elezanumab  (Synonyms: ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab))

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism^[1][2].

Human IgG1 lambda2

Human IgG1 lambda2, Isotype Control

Human

RGMA

Elezanumab (ABT-555; AE12-1Y-QL; 1-10 mg/kg; IV; once a week for 5 doses) promotes axonal regeneration and prevents retinal nerve fiber layer degeneration in the optic nerve crush and optic neuritis models (female Lewis rats)^[1].
Elezanumab (0.01, 0.1, 1, 10 mg/kg; IV; once a week for 3 doses ) promotes axonal regeneration and remyelination, decreases inflammatory lesion area and improves functional recovery in the spinal targeted experimental autoimmune encephalomyelitis (EAE) model (female Lewis rats)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

56963  [NCBI]

Q96B86

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.44 kDa

1791416-49-3

Liquid

Colorless to light yellow

[Elezanumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda2

• 
  Immobilized Human RGMA Protein (His Tag) can bind Elezanumab. The EC₅₀ for this effect is 2.09 ng/mL.

• [1]. Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492.  [Content Brief]

  [2]. Peer B Jacobson, et al. Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. Neurobiol Dis. 2021 Jul;155:105385.  [Content Brief]